Volume 6, Issue 1: The Current State of CFTR Modification

e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.

(Volume 6, Issue 1)


Target Audience

Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to: 

  • Describe the long-term benefits of ivacaftor therapy
  • Evaluate the effects of ivacaftor in people with non-G551D CFTR mutations
  • Explain the impact of lumacaftor/ivacaftor in people with cystic fibrosis due to two F508del CFTR mutations


Additional information
Contact email: 
Course summary
Available credit: 
  • 1.00 ANCC
  • 1.00 Attendance
Registration opens: 
Registration closes: 
Peter J. Mogayzel, Jr., MD, PhD
Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University
Baltimore, MD


Dr. Peter Mogayzel reports he has no relevant relationships with a commercial entity.

Unlabeled/Unapproved Uses

Dr. Peter Mogayzel reports there will be no discussions of off-label or unapproved uses of drugs or products.


Available Credit

  • 1.00 ANCC
  • 1.00 Attendance


Please login or register to take this course.

Required Hardware/software

Make sure your Adobe flash is updated by clicking HERE